Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomised Controlled, Phase II Clinical Study of Tirilizumab in Combination with Albumin-bound Paclitaxel with Cisplatin for Neoadjuvant and Adjuvant Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma

NCT06470217 is registered in ClinicalTrials.gov with Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University as lead sponsor.

NCT NCT06470217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06470217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomised Controlled, Phase II Clinical Study of Tirilizumab in Combination with Albumin-bound Paclitaxel with Cisplatin for Neoadjuvant and Adjuvant Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma
Lead sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase
Phase 2
Overall status
Recruiting
Start date
June 19, 2024
Completion date
June 19, 2027
Enrollment
116 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced head and neck squamous cell carcinoma